204 related articles for article (PubMed ID: 16208172)
1. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
Zantut-Wittmann DE; Ramos CD; Santos AO; Lima MM; Panzan AD; Facuri FV; Etchebehere EC; Lima MC; Tambascia MA; Camargo EE
Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
[TBL] [Abstract][Full Text] [Related]
2.
Zhao L; Zhang W; Xin Y; Wen Q; Bail L; Guan F; Bin J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):349-353. PubMed ID: 30413358
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.
Moura-Neto A; Mosci C; Santos AO; Amorim BJ; de Lima MC; Etchebehere EC; Tambascia MA; Ramos CD; Zantut-Wittmann DE
Clin Nucl Med; 2012 Jun; 37(6):550-4. PubMed ID: 22614185
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of (99m)Tc-pertechnetate thyroid scintigraphy in radioiodine therapy in a cohort of Chinese Graves' disease patients: a pilot clinical study.
Hou H; Hu S; Fan R; Sun W; Zhang X; Tian M
Biomed Res Int; 2015; 2015():974689. PubMed ID: 25879041
[TBL] [Abstract][Full Text] [Related]
5. [Predictors of the efficacy of radioiodine therapy of Graves' disease in children and adolescents].
Rumyantsev PO; Saenko VA; Dzeytova DS; Trukhin AA; Sheremeta MS; Slashchuk KY; Degtyarev MV; Serzhenko SS; Yasuchenia VS; Zakharova SM; Sirota YI
Probl Endokrinol (Mosk); 2020 Oct; 66(4):68-76. PubMed ID: 33351361
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
7. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
8. [Prediction of remission in Graves' disease after thionamide therapy by technetium-99m early uptake].
Misaki T; Dokoh S; Koh T; Shimbo S; Hidaka A; Iida Y; Kasagi K; Konishi J
Kaku Igaku; 1991 Feb; 28(2):157-61. PubMed ID: 1711131
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication?
Kobe C; Weber I; Eschner W; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(4):153-6. PubMed ID: 18690374
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
[TBL] [Abstract][Full Text] [Related]
11. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators.
Prakash R
Eur J Nucl Med; 1996 Feb; 23(2):118-22. PubMed ID: 8925844
[TBL] [Abstract][Full Text] [Related]
12. Strategies of radioiodine therapy for Graves' disease.
Lind P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
[TBL] [Abstract][Full Text] [Related]
13. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
14. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
15. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
16. Thyrotoxic Graves' disease with normal thyroidal technetium-99m pertechnetate uptake.
Ikekubo K; Hino M; Ito H; Koh T; Ishihara T; Kurahachi H; Kasagi K; Hidaka A; Mori T
Ann Nucl Med; 1990 Jul; 4(2):43-8. PubMed ID: 2171608
[TBL] [Abstract][Full Text] [Related]
17. Scintigraphic findings of the thyroid in euthyroid ophthalmic Graves' disease.
Kasagi K; Hidaka A; Misaki T; Miyamoto S; Takeuchi R; Sakahara H; Sasayama S; Iida Y; Konishi J
J Nucl Med; 1994 May; 35(5):811-7. PubMed ID: 8176463
[TBL] [Abstract][Full Text] [Related]
18. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
[TBL] [Abstract][Full Text] [Related]
19. The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves' hyperthyroidism.
Sekulić V; Rajić M; Vlajković M; Ilić S; Stević M; Kojić M
Ann Nucl Med; 2017 Dec; 31(10):744-751. PubMed ID: 28895066
[TBL] [Abstract][Full Text] [Related]
20. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]